Atropine Injection
Atropine Sulphate
0.6 mg/ml
Edruc Ltd.
| Pack size | 10's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 5.00 AED |
Available as:
Indications
Atropine Injection is used for:
Bradycardia, Organophosphorus poisoning, Anesthesia Premedication, Bronchospasm
Adult Dose
Adult
Antisialagogue or for antivagal effects:
An initial single dose of 0.5 mg to 1 mg
Antidote for organophosphorus or muscarinic mushroom poisoning:
An initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes
Bradyasystolic cardiac arrest:
1 mg dose, repeated every 3-5 minutes if asystole persists
Patients with Coronary Artery Disease:
Limit the total dose to 0.03 mg/kg to 0.04 mg/kg
Anesthesia Premedication
0.4-0.6 mg IV/IM/SC 30-60 minutes before anesthesia; repeat q4-6hr PRN
Sinus Bradycardia (ACLS)
0.5-1 mg or 0.04 mg/kg IV q5min, no more than 3 mg
Organophosphorus poisoning
Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears.
In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinization is maintained for at least 2 days and continued for as long as symptoms are present.
Bronchospasm
0.025 mg/kg in 2.5 mL NS q6-8hr via nebulizer; no more than 2.5 mg/dose
Asystole/Pulseless Electrical Activity (ACLS)
1 mg IV q3-5min PRN if asystole persist up to 0.04 mg/kg
Child Dose
Anesthesia Premedication
<5 kg: 0.02 mg/kg/dose 30-60 minutes preop; then q4-6hr PRN
>5 kg: 0.01-0.02 mg/kg IV/IM/SC; no more than 0.4 mg
Sinus Bradycardia
0.02 mg/kg IV/IO q5min for 2-3 doses PRN; single dose no less than: 0.1 no more than 0.5 mg (children), 1 mg (adolescents)
Total: No more than: 1 mg (children)
Bronchospasm
0.025-0.05 mg/kg in 2.5 mL NS q6-8hr via nebulizer; no more than 2.5 mg/dose
Organophosphate or Carbamate Poisoning
IV: 0.03-0.05 mg/kg IV/IM/IO/ET q10-20min PRN to effect; then q1-4hr for at least 24 hours
Renal Dose
Administration
IV Administration
Give into large vein or IV tubing over 1-2 min
Contra Indications
Glaucoma, chronic respiratory disease, sick sinus syndrome, thyrotoxicosis, cardiac failure, pyloric stenosis, prostatic hypertrophy.
Precautions
Tachycardia
When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand.
Acute Glaucoma
Atropine may precipitate acute glaucoma.
Pyloric Obstruction
Atropine may convert partial organic pyloric stenosis into complete obstruction.
Complete Urinary Retention
Atropine may lead to complete urinary retention in patients with prostatic hypertrophy.
Viscid Plugs
Atropine may cause inspissation of bronchial secretions and the formation of viscid plugs in patients with chronic lung disease.
Monitoring Parameters
Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block Since atropine has a shorter duration of action than neostigmine, late unopposed
bradycardia may result; close monitoring of the patient is necessary.
Pregnancy-Lactation
Pregnancy
Drug readily crosses the placental barrier and enter fetal circulation; there are no adequate data on the developmental risk associated with the use of atropine in pregnant women; adequate animal reproduction studies have not been conducted with atropine
Lactation
Drug reported to be excreted in human milk; there are no data on the effects of atropine on breastfed infants or effects on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed infant from therapy or from the underlying maternal condition
Interactions
Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.
Mexiletine Decreases rate of mexiletine absorption.
Contraindicated (0)
Serious - Use Alternative (4)
glycopyrronium tosylate topical
pramlintide
sofpironium topical
umeclidinium bromide/vilanterol inhaled
Adverse Effects
Side effects of Atropine Sulphate :
Frequency Not Defined
Anticholinergic symptoms (mydriasis, hyperthermia, tachycardia, cardiac arrhythmia, delayed gastric emptying)
Ataxia
Fever
Headache
Insomnia
Dry mouth
Anhidrosis
Urticaria
Urinary hesitancy
Dry skin
Blurred vision
Cycloplegia
Photophobia
Anhidrosis
Palpitation
Dyspnea
Paralytic ileus
Pulmonary edema
Nasal dryness
Xerophthalmia
Constipation
May increase IOP in predisposed patients
May cause CNS disturbances (especially in pediatric patients)
Potentially Fatal: Atrial arrhythmias, AV dissociation, multiple ventricular ectopics.
Mechanism of Action
Atropine is an anticholinergic agent which competitively blocks the muscarinic receptors in peripheral tissues such as the heart, intestines, bronchial muscles, iris and secretory glands. Some central stimulation may occur. Atropine abolishes bradycardia and reduces heart block due to vagal activity. Smooth muscles in the bronchi and gut are relaxed while glandular secretions are reduced. It also has mydriatic and cycloplegic effect.
Note
Atropine 0.6 mg/ml Injection manufactured by Edruc Ltd.. Its generic name is Atropine Sulphate. Atropine is availble in Bangladesh.
Farmaco BD drug index information on Atropine Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.